Several factors likely hindered our ability to detect treatment-related PBTL p16 increases, including the limited number of paired samples acquired due to COVID-19 restrictions and other events, therapeutic diversity even within the same treatment group, and changes in disease burden since all the patients analyzed were responders. The gene discussed is CDKN2A; the disease is COVID-19.